Trading Concept
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
No Result
View All Result
Trading Concept
No Result
View All Result
Home Trading News

J&J plans to split into two companies, separating consumer products and pharmaceutical businesses

by
November 12, 2021
in Trading News
0
0
SHARES
0
VIEWS
Share on FacebookShare on Twitter

RELATED POSTS

Cathie Wood says rising rates hit her strategy like an earthquake and cyclical stocks are next

Potentially deadly fungus is spreading at an ‘alarming rate,’ CDC says

Health-care conglomerate Johnson & Johnson announced plans Friday to split its consumer products business from its pharmaceutical and medical device operations, creating two publicly traded companies. The news sent shares higher in premarket trading.

The separation will sheer off its household products unit, maker of Band-Aid bandages, Aveeno and Neutrogena skin care products and Listerine, from its riskier, but faster-growing division that makes and sells prescription drugs and medical devices, including its Covid-19 vaccine.

“Following a comprehensive review, the board and management team believe that the planned separation of the consumer health business is the best way to accelerate our efforts to serve patients, consumers, and healthcare professionals, create opportunities for our talented global team, drive profitable growth, and – most importantly – improve healthcare outcomes for people around the world,” outgoing CEO Alex Gorsky said in a statement.

The company said it hopes to complete the transaction in 18 to 24 months. The pharmaceutical and medical device division, which includes advanced technologies like robotics and AI, would retain the name Johnson & Johnson and keep J&J’s incoming CEO Joaquin Duato at its helm.

Gorsky told CNBC that the company hasn’t determined a name yet for the new, publicly-traded consumer business.

He said the decision to break up the company had been discussed by its board for “some time” as it would bring “tremendous opportunity” to stakeholders.

“It’s in the best long-term interest of all our stakeholders,” he said on “Squawk Box.” “Our goal is really to create two global leaders – a pharmaceutical and medical device business that has great potential today … and of course, the consumer business that’s got iconic brands.”

Duato is taking over the role in January as previously planned. Those segments are expected to generate roughly $77 billion in revenue while the consumer products division is forecast to sell about $15 billion in products this year, the company said.

Its yet-to-be-named consumer products company will also inherit litigation stemming from lawsuits over claims that its Johnson’s Baby Powder causes cancer, allegations the company has vehemently denied.

Gorsky said the consumer division has four brands alone that generate over $1 billion dollars in annual sales. By separating it, the company can provide “even more agility” and “a better opportunity for capital allocation,” he said.

Shares of J&J were up more than 3% in premarket trading after the announcement.

J&J was already undergoing a major transition with Gorsky’s departure as CEO. He will remain on as executive chairman of the new J&J, the company said.

Additionally, the company said it planned to keep its total dividend “at least at the same level” following the change. J&J currently sports a dividend yield of about 2.6%.

The announcement comes just days after General Electric said it plans to split into three separate companies, spinning out its medical unit from its aviation and energy units.

-CNBC’s Berkeley Lovelace Jr. contributed to this report.

ShareTweetPin

Related Posts

Cathie Wood says rising rates hit her strategy like an earthquake and cyclical stocks are next

by
March 21, 2023
0

Ark Invest's Cathie Wood said rapid interest rate hikes over the past year are now starting to hit cyclical pockets...

Potentially deadly fungus is spreading at an ‘alarming rate,’ CDC says

by
March 21, 2023
0

Candida auris is a yeast responsible for many infections. Resistant to most anti-fungal drugs, this fungus causes several deaths worldwide....

Bitcoin, ether build on recent gains as investors await Fed rate hike decision

by
March 21, 2023
0

Pedestrians walk past an advertisement displaying a Bitcoin cryptocurrency token on February 15, 2022 in Hong Kong, China. Anthony Kwan...

Home sales spike 14.5% in February as the median price drops for the first time in over a decade

by
March 21, 2023
0

Sales of previously owned homes rose 14.5% in February compared with January, according to a seasonally adjusted count by the...

GameStop stock soars after retailer posts first quarterly profit in two years

by
March 21, 2023
0

In this article GME Follow your favorite stocksCREATE FREE ACCOUNT A GameStop store operates in a strip mall on March...

Next Post

Warby Parker shares drop as eyeglass retailer's losses widen in third quarter

Ark Invest's Cathie Wood buys the dip on 3D Systems

Leave a Reply Cancel reply

Your email address will not be published. Required fields are marked *

email

Get the daily email about stock.

Please Enter Your Email Address:



By opting in you agree to our Privacy Policy. You also agree to receive emails from us and our affiliates. Remember that you can opt-out any time, we hate spam too!

MOST VIEWED

  • WHO says Covid vaccine booster programs will prolong pandemic

    0 shares
    Share 0 Tweet 0
  • Forget Tesla — this auto stock is the one to buy right now, analyst says

    0 shares
    Share 0 Tweet 0
  • Spin or Split? AT&T Has a Big Decision to Make on Discovery Stake.

    0 shares
    Share 0 Tweet 0
  • Here’s how Carl Icahn is positioning for a possible recession in America

    0 shares
    Share 0 Tweet 0
  • Some lawmakers and their families are betting thousands of dollars on crypto

    0 shares
    Share 0 Tweet 0
  • Home
  • Trading News
  • Email Whitelisting
  • Privacy Policy
All rights reserved by tradingconcept.net
No Result
View All Result
  • Email Whitelisting
  • Home
  • Privacy Policy

All rights reserved by www.tradingconcept.net